Aurobindo Pharma announced that Eugia Pharma B.V., its wholly owned stepdown subsidiary, has incorporated a new wholly owned subsidiary in Chile named Eugia Pharma Chile SpA. The new subsidiary aims to expand the company’s pharmaceutical products business in Chile. This strategic move reinforces Aurobindo’s commitment to growth through strategic expansion and strengthens its global presence. The incorporation was finalized on October 7, 2025.
Strategic Expansion into Chile
Aurobindo Pharma is extending its reach into Latin America with the establishment of Eugia Pharma Chile SpA. This new entity is a wholly owned subsidiary of Eugia Pharma B.V., which is a stepdown subsidiary of Aurobindo Pharma. The primary objective of this incorporation is to further expand the pharmaceutical business of Aurobindo in the Chilean market.
Subsidiary Details
The incorporation of Eugia Pharma Chile SpA was completed on October 7, 2025, with official documentation finalized on October 22, 2025. The initial investment in the subsidiary includes a share capital of CLP 1,000,000 (USD 1,050), divided into 100 shares each with a nominal value of CLP 10,000. Aurobindo Pharma holds 100% ownership of the new subsidiary.
Future Outlook
With this strategic move, Aurobindo Pharma is set to strengthen its global footprint and bring its range of pharmaceutical products to the Chilean market. This expansion aligns with the company’s long-term growth strategy. No governmental or regulatory approvals were required for the acquisition.
Source: BSE
